Market Overview

UPDATE: Jefferies Raises PT on Eli Lilly & Co. as Least-Preferred Name

Share:
Related LLY
Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers
Benzinga's Top Upgrades
Transition Therapeutics licenses androgen receptor modulator from Lilly (Seeking Alpha)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated an Underperform rating on Eli Lilly & Co. (NYSE: LLY), and slightly raised the price target from $43.00 to $44.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Eli Lilly & Co. closed on Tuesday at $56.74.

Latest Ratings for LLY

DateFirmActionFromTo
Apr 2015CitigroupUpgradesNeutralBuy
Apr 2015BMO CapitalMaintainsMarket Perform
Mar 2015SunTrust Robinson HumphreyMaintainsBuy

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

Around the Web, We're Loving...